Research Topics
| O HeikinheimoSummaryAffiliation: University of Helsinki Country: Finland Publications
| Collaborators
|
Detail Information
Publications
The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIVOskari Heikinheimo
Department of Obstetrics and Gynaecology, University of Helsinki, Finland
Hum Reprod 21:2857-61. 2006..The levonorgestrel-releasing intrauterine system (LNG-IUS) is a highly effective contraceptive with additional health benefits. The objective of this study was to evaluate the effects of the LNG-IUS among HIV-infected women...
The molecular mechanisms of oocyte maturation and early embryonic development are unveiling new insights into reproductive medicineO Heikinheimo
Department of Biomedicine, University of Helsinki, Finland
Mol Hum Reprod 4:745-56. 1998..We acknowledge that most of the data presented comes from species other than human, therefore at present the full biological role of the proposed regulatory pathways and control mechanisms for human biology remains speculative...
Advanced cervical pregnancy: uterus-sparing therapy initiated with a combination of methotrexate and mifepristone followed by evacuation and local hemostatic measuresOskari Heikinheimo
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Acta Obstet Gynecol Scand 83:211-3. 2004
Mifepristone may inhibit the midcycle gonadotropin surge at both ovarian and pituitary sites of actionOskari Heikinheimo
Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
Fertil Steril 84:1545-6. 2005..In the current work, late-follicular phase administration of mifepristone resulted in decrease in both circulating FSH and inhibin B, suggesting both central and ovarian sites of action...
The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin actionOskari Heikinheimo
Department of Obstetrics and Gynecology, University of Helsinki, P O Box 140, SF 00029, HUS, Helsinki, Finland
Contraception 68:421-6. 2003..It remains to be seen whether the newly synthesized, more selective antiprogestins will prove more efficacious in the clinical arena...
Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot studyOskari Heikinheimo
Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF 00029 HUS, Helsinki, Finland
Hum Reprod 22:2515-22. 2007..We compared the effects of intrauterine release of a highly specific PA, ZK230211, to those of a progestin using the levonorgestrel-releasing intrauterine system (LNG-IUS)...
Termination of early pregnancy using flexible, low-dose mifepristone-misoprostol regimensOskari Heikinheimo
Department of Obstetrics and Gynecology, University of Helsinki, PO Box 140, SF 00029 Helsinki, Finland
Contraception 76:456-60. 2007..We examined the effect of a change in protocol from a fixed mifepristone-misoprostol interval to a flexible one on the efficacy and uptake of medical abortion. In addition, risk factors of incomplete abortions were evaluated...
Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administrationO Heikinheimo
Steroid Research Laboratory, Department of Biomedicine, University of Helsinki, Helsinki, Finland
Steroids 65:831-6. 2000..However, the lack of change in SHBG and the low E(2) levels suggest that enhanced systemic estrogen effects are unlikely during long-term mifepristone treatment...
Age, parity, history of abortion and contraceptive choices affect the risk of repeat abortionOskari Heikinheimo
Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
Contraception 78:149-54. 2008..However, risk factors as regards repeat abortion are poorly understood. We characterized risk factors related to sociodemographic characteristics, history of abortion and post-abortal contraception...
Clinical pharmacokinetics of mifepristoneO Heikinheimo
Department of Biomedicine, University of Helsinki, Finland
Clin Pharmacokinet 33:7-17. 1997..However, it is hoped that the eventual introduction of new antiprogesterone molecules by several manufacturers will enhance the availability of this important class of new drugs...
Contraception and HIV infection in womenOskari Heikinheimo
Department of Obstetrics and Gynaecology, University of Helsinki, Finland
Hum Reprod Update 15:165-76. 2009..This review aims to show the effect of contraceptive choices on risk of HIV and on the course of disease in women with HIV...
Can the outcome of the next pregnancy be predicted at the time of induced abortion?Oskari Heikinheimo
Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF 00029, HUS, Finland
Hum Reprod 24:820-6. 2009..Factors predicting the outcome of the next pregnancy following termination of pregnancy (TOP) are poorly known...
The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up studyOskari Heikinheimo
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Am J Obstet Gynecol 204:126.e1-4. 2011..We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device...
Effect of antiprogesterone mifepristone followed by misoprostol on circulating leptin in early pregnancyHelena Honkanen
Department of Obstetrics and Gynecology, University of Helsinki, SF-00029 HUS, Helsinki, Finland
Acta Obstet Gynecol Scand 84:134-9. 2005..Moreover, the significant correlation between the changes in leptin and those of P4 and E2 at the time of luteolysis suggests that corpus luteum may also play a role in the regulation of circulating leptin in early pregnancy...
Frequency and risk factors for repeat abortions after surgical compared with medical termination of pregnancyMaarit Niinimäki
Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland
Obstet Gynecol 113:845-52. 2009..To compare the frequency and risk factors for repeat abortions after surgical compared with medical termination of pregnancy...
Medical versus surgical termination of pregnancy in primigravid women-is the next delivery differently at risk? A population-based register studyJ Mannisto
Department of Obstetrics and Gynaecology, University Hospital of Oulu, Oulu, Finland
BJOG 120:331-7. 2013..To compare the effect of medical versus surgical termination of pregnancy (TOP), performed in primigravid women, on subsequent delivery...
Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding studyM Haukkamaa
Department of Medical Chemistry, University of Helsinki, Finland
Contraception 45:49-55. 1992..This method, using a single 4 cm subcutaneous implant releasing the progestin ST-1435 with a life-time of two years, represents a promising alternative for inhibition of ovulation and contraception...
The progestin ST 1435--rapid metabolism in manO Heikinheimo
Department of Medical Chemistry, University of Helsinki, Finland
Contraception 50:275-89. 1994..However, the rapid metabolism seen after oral intake can be successfully circumvented by sustained parenteral administration of ST 1435...
A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistryM Laurikka-Routti
Department of Medical Chemistry, University of Helsinki, Finland
Contraception 42:111-20. 1990..This contraceptive vaginal ring presents a good method of contraception, showing good bleeding control and no harmful metabolic effects...
Transdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in salivaM Haukkamaa
Department of Medical Chemistry, University of Helsinki, Finland
Contraception 44:269-76. 1991..However, the concentrations of serum and salivary ST-1435 were not directly correlated in different individuals. Transdermal application of ST-1435 might offer a good alternative for systemic progestin treatment...
The learning curve is rapid in medical termination of pregnancy--first-year results from the Helsinki areaSatu Suhonen
Women's Hospital, Department of Obstetrics and Gynecology, University of Helsinki, PO Box 140, FIN-00029, Helsinki, Finland
Contraception 67:223-7. 2003..We conclude that the learning curve in medical termination of pregnancy is rapid, and results comparable to those in centers with extensive experience with the method can be reached within the first year...
Experience with the levonorgestrel-releasing intrauterine system among HIV-infected womenPäivi Lehtovirta
Department of Obstetrics and Gynecology, University of Helsinki, SF 00029 Helsinki, Finland
Contraception 75:37-9. 2007..Yet, little is known about LNG-IUS use in HIV-infected women...
The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancyHelena Honkanen
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki and Department of Biomedicine, University of Helsinki, Helsinki, Finland
Hum Reprod 17:2315-9. 2002..CONCLUSIONS: The route and duration of misoprostol administration have no effect on the kinetics of serum hCG or progesterone during medical termination of early pregnancy...
Young age and termination of pregnancy during the second trimester are risk factors for repeat second-trimester abortionMaarit J Mentula
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Am J Obstet Gynecol 203:107.e1-7. 2010..The objective of the study was to characterize women undergoing a termination of pregnancy (TOP) during the second trimester and to evaluate the risk factors and timing of repeat TOP...
Misoprostol-only versus mifepristone plus misoprostol in induction of labor following intrauterine fetal deathWilma Väyrynen
Department of Obstetrics and Gynecology, University of Helsinki, Finland
Acta Obstet Gynecol Scand 86:701-5. 2007..Both misoprostol-alone and a combination of mifepristone plus misoprostol have been used in induction of labor in cases of intrauterine fetal death (IUFD)...
One- and 2-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancyOskari Heikinheimo
Women s Hospital, Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
Reprod Biomed Online 8:236-9. 2004..001), in the 1- and 2-day interval groups respectively. Thus both 1- and 2-day mifepristone-misoprostol intervals are valuable in termination of second-trimester pregnancy...
Pregnancy outcome among HIV-infected women in the Helsinki metropolitan areaPäivi Lehtovirta
Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
Acta Obstet Gynecol Scand 84:945-50. 2005..The incidence of HIV infection has remained low in Finland. Universal antenatal screening has been offered to all pregnant women since 1998...
Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine systemOskari Heikinheimo
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Contraception 81:481-6. 2010..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
Trends in teenage termination of pregnancy and its risk factors: a population-based study in Finland, 1987-2009S Leppälahti
Department of Obstetrics and Gynaecology, Katiloopisto Hospital, University of Helsinki and Helsinki University Central Hospital, PO Box 610, 00029 HUS, Helsinki, Finland
Hum Reprod 27:2829-36. 2012..The rising rate of repeat TOP is alarming and may represent a sign of marginalization among these girls. All efforts to maintain a low rate of teenage pregnancy are welcomed...
Mifepristone: a potential contraceptiveO Heikinheimo
University of Helsinki, Finland
Clin Obstet Gynecol 39:461-8. 1996....
Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine systemO Heikinheimo
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PO Box 610, 00029 HUS Helsinki, Finland
Hum Reprod 25:1423-7. 2010..The objective of this study was to analyse the possible factors which may predict the bleeding pattern during the first year of use of a second LNG-IUS...
Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception?Riikka Leminen
Department of Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland
Eur J Endocrinol 152:411-8. 2005..We studied the endocrine actions of 10 mg mifepristone administered orally as a single dose to eight healthy volunteers (aged 20-45 years) during the late follicular phase...
Risk factors, diagnosis and prognosis of cervical intraepithelial neoplasia among HIV-infected womenPäivi Lehtovirta
Department of Obstetrics and Gynaecology, University of Helsinki, PO Box 140, SF00029, Helsinki, Finland
Int J STD AIDS 19:37-41. 2008..However, the patients with and without CIN could not be distinguished on the basis of previously described risk factors. Regular follow-up by means of Pap smears is warranted in all HIV-infected women...
Hormonal contraception and mental health: results of a population-based studyE Toffol
Department of Mental Health and Substance Abuse Services, National Institute for Health and Welfare THL, Helsinki, Finland
Hum Reprod 26:3085-93. 2011..The aim of this study was to analyse the association between the use of OCs and the LNG-IUS and psychological well-being and psychopathology...
Parenteral administration of progestin Nestorone to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation?O Heikinheimo
Steroid Research Laboratory, Institute of Biomedicine, Department of Obstetrics and Gynecology, University of Helsinki, Finland
Hum Reprod 14:1993-7. 1999..These data confirm that NES in milk is rapidly metabolized by the suckling infant. Therefore, NES appears to be an ideal hormonal contraceptive for use during lactation...
Oestrogen receptors and small nuclear ring finger protein 4 (RNF4) in malignant ovarian germ cell tumoursJonna Salonen
Paediatric Research Centre, Children s Hospital, Helsinki, Finland
Mol Cell Endocrinol 307:205-10. 2009..Neither E2 nor ICI 182,780 had an effect on the proliferation of NCC-IT cells as assessed by flow cytometric analysis. Our results suggest that oestrogen signalling has a role in malignant ovarian germ cell tumours...
Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcomaRiitta Koivisto Korander
Department of Obstetrics and Gynecology, University of Helsinki, Finland
Obstet Gynecol 109:512-4. 2007..Leiomyomata and uterine leiomyosarcomas share some common features, and they both often express progesterone receptors. Thus, treatment of uterine leiomyosarcomas with antiprogestins has been suggested...
Immediate complications after medical compared with surgical termination of pregnancyMaarit Niinimäki
Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
Obstet Gynecol 114:795-804. 2009..To estimate the immediate adverse events and safety of medical compared with surgical abortion using high-quality registry data...
Prevalence and risk factors of squamous intraepithelial lesions of the cervix among HIV-infected women - a long-term follow-up study in a low-prevalence populationPäivi Lehtovirta
Department of Obstetrics and Gynaecology, University of Helsinki, Finland
Int J STD AIDS 17:831-4. 2006..04) as well as in women displaying high initial HIV viral load (P = 0.01). Our results from a low HIV-incidence population re-emphasize the importance of guidelines for cytologic screening of HIV-seropositive women...
Pharmacokinetics of 10 mg of mifepristoneRiikka Leminen
Department of Obstetrics and Gynecology, University of Helsinki, P.O. Box 140, SF-00029, HUS, Helsinki, Finland
Contraception 68:427-9. 2003..9 days. The pharmacokinetic data on 10 mg mifepristone are in line with previous pharmacokinetic and clinical data, and encourage further development of the 10-mg dose in emergency contraception...
Rectovaginal endometriosis-characteristics of operative treatment and factors predicting bowel resectionSatu Tarjanne
Department of Obstetrics and Gynecology, University of Helsinki, Finland
J Minim Invasive Gynecol 16:302-6. 2009..The purpose of this study was to characterize operative treatment of patients with rectovaginal endometriosis (RVE), with special emphasis on factors predicting bowel resection...
Termination of pregnancy with mifepristone and prostaglandin suppresses transiently circulating glucocorticoid bioactivityOskari Heikinheimo
Department of Obstetrics and Gynecology and Institute of Biomedicine, University of Helsinki and Helsinki University Central Hospital, FIN-00014 Helsinki, Finland
J Clin Endocrinol Metab 88:323-6. 2003..We conclude that 200 mg mifepristone elicits a significant suppression of serum GBA, to one third of the pretreatment value, despite the compensatory increase in the serum cortisol concentration...
Changes in vaginal morphology, steroid receptor and natural antimicrobial content following treatment with low-dose mifepristoneNitish Narvekar
Contraceptive Development Network, Centre for Reproductive Biology, University of Edinburgh, The Queen s Medical Research Institute, 47 Little France Crescent, EH16 4TJ Edinburgh, UK
Contraception 75:271-80. 2007..We investigate the effects of mifepristone on vaginal thickness, steroid receptor and natural antimicrobial content and pharmacokinetics of mifepristone...
[Is monthly menstruation necessary?]Oskari Heikinheimo
HYKS n naistenklinikka, HUS
Duodecim 121:245-6. 2005
[Estrogens, progesterones and the mammary gland]Oskari Heikinheimo
HYKS:in naistenklinikka, HUS
Duodecim 121:525-32. 2005
[Pregnancy and labor of a HIV-positive woman]Oskari Heikinheimo
HYKS:n naistenklinikka PL 140, 00029 HUS
Duodecim 118:1405-9. 2002
Long-cycle combined contraception: less bleeding and increased subject satisfactionOskari Heikinheimo
Acta Obstet Gynecol Scand 85:517-8. 2006
[Gynecological tumors during pregnancy]Tua Annanmaki
Suomen Lääkätieteen Säätiö PL 713, 00101 Helsinki
Duodecim 120:1085-90. 2004
